PureTech Health plcPRTC has confirmed that it is in talks about a possible tie-up with Nektar TherapeuticsNKTR.
In April, Nektar Therapeutics announced a new strategic plan to prioritize key research and development efforts and cut 70% of its workforce, including several changes to its executive team.
Responding to press speculation, PureTech said it has exchanged indicative, non-binding proposals with Nektar Therapeutics regarding a possible combination, which may include an offer for the share capital of PureTech.
“PureTech and Nektar remain in discussions regarding the proposal. There can be no certainty that any firm offer will be made, nor as to the terms of any such offer. A further announcement will be made as and when appropriate,” the company said.
Nektar will have until Nov. 3 to make a formal offer.
Price Action: PRTC shares are down 20.03% at $24.80, and NKTR shares are down 1.03% at $3.34 on the last check Friday.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
